

AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior listings and versions:

1 to 18. (canceled).

19. (previously presented): A method for immunizing a vertebrate subject against at least one selected antigen, the method comprising the step of parenterally administering to the vertebrate subject an immunologically effective amount of

a) a parenteral adjuvant comprising a detoxified mutant of an *E. coli* heat-labile (LT) ADP-ribosylating toxin in combination with a pharmaceutically acceptable vehicle, wherein said detoxified mutant is LT-R72; and

b) at least one selected antigen.

20 to 24. (canceled).

25. (currently amended): A The method according to claim 19, wherein the adjuvant and the antigen are administered subcutaneously, transcutaneously or intramuscularly.

26. (currently amended): A The method according to claim 19, wherein the pharmaceutically acceptable vehicle is a topical vehicle.

27. (currently amended): A The method according to claim 26, wherein the adjuvant and the antigen are administered transcutaneously.

28. (currently amended): A The method according to claim 19, wherein the adjuvant is administered to the vertebrate subject prior to administering the selected antigen.

29. (currently amended): A The method according to claim 19, wherein the adjuvant is administered to the vertebrate subject subsequent to administering the selected antigen.

30. (currently amended): A The method according to claim 19, wherein the antigen is administered to the vertebrate subject concurrent with administering the selected antigen.

31. (previously presented): The method of claim 19, wherein said antigen is a viral antigen.

32. (previously presented): The method of claim 31, wherein said viral antigen is selected from the group consisting of an influenza antigen, a herpes simplex virus (HSV) antigen, a human immunodeficiency virus (HIV) antigen, a cytomegalovirus (CMV) antigen, a hepatitis C virus (HCV) antigen, a delta hepatitis virus (HDV) antigen, a poliovirus antigen, a hepatitis A virus (HAV) antigen, an Epstein-Barr virus (EBV) antigen, a varicella zoster virus (VZV) antigen, and a respiratory syncytial virus (RSV) antigen.

33. (previously presented): The method of claim 32, wherein said viral antigen is an influenza virus antigen.

34. (previously presented): The method of claim 32, wherein said viral antigen is a poliovirus antigen.

35. (previously presented): The method of claim 32, wherein said viral antigen is a RSV antigen.

36. (previously presented): The method of claim 19, wherein said antigen is a bacterial antigen.

37. (currently amended): The method of claim 36, wherein said bacterial antigen is from a bacterium selected from the group consisting of *Bordetella pertussis* ~~antigens~~, *Helicobacter pylori* ~~antigens~~, ~~streptococcal antigens~~, meningococcus A ~~antigens~~, meningococcus B ~~antigens~~, and meningococcus C ~~antigens~~.

38. (currently amended): The method of claim 37, wherein said bacterial antigen is a from *Bordetella pertussis* ~~antigen~~.

39. currently amended): The method of claim 37, wherein said bacterial antigen is a from *Helicobacter pylori* ~~antigen~~.

40. (canceled).

41. (currently amended): The method of claim 37, wherein said bacterial antigen is from
a meningococcus A ~~antigen~~.

42. (currently amended): The method of claim 37, wherein said bacterial antigen is from
a meningococcus B ~~antigen~~.

43. (currently amended): The method of claim 37, wherein said bacterial antigen is from
a meningococcus C ~~antigen~~.